Affordable High Quality Generic Products for All
致力研發利基型學名藥以為全球人類提供可負
擔且高品質的藥品、服務及提升人民健康福祉
Lotus Pharmaceutical Co., Ltd.
INTRODUCTION
Lotus aggressively follows the United Nation’s Sustainable Development Goals (SDGs) Health and Wellbeing, Employment and Economic Growth and Reduces Inequality, to gradually reduce patients’ burden of medicines and social costs, and delays caused by high medical expenses. Through the Company’s sustainable development efforts, Lotus wishes to provide patients with affordable treatment and equal medical options, making people healthier and live longer while creating a better planet in advance.
FRAMEWORK AND STRATEGY
Lotus marked by several notable achievements delivered through the Company’s unique turnkey business model and first-to-market global launches. The Company successfully launched Buprenorphine/Naloxone sublingual film for the treatment of opioid dependence in the US, Lenalidomide for the treatment of multiple myeloma in Europe, Gefitinib for the treatment of nonsmall-cell lung cancer in 20 European markets on patent expiry date, and the first generic Vinorelbine in form of softgel capsules with high entry barrier across development and manufacturing. Our tremendous efforts have been highly recognised by major awards, including Outstanding Bio Enterprise from BIO Asia – Taiwan.ACHIEVEMENT AND IMPACT
Lotus’s generic anti-addiction drug Buprenorphine/Naloxone which is successfully marketed in US, is a good example. The price of Buprenorphine/Naloxone is only one-third of the originator. Since Buprenorphine/Naloxone was launched in 2019, accessibility of such anti-addiction drugs has been greatly improved. The market shares substantially expanded to 36% in July this year, comparable to the originator. After the Company launched Buprenorphine/Naloxone in US market, the overall market prescriptions grew 34% from 4 million to near 6.5 million while the burden of drugs and social costs have been reduced 20% accordinglyFUTURE DIRECTION
Considering high cost of oncology treatments, the accessibility of drug for patients and new generic products trend, Lotus will keep its unique R&D and manufacturing niche, be in line with the global market resources from Alvogen and cooperate with first-class partners to provide affordable drugs in the growing oncology market. The Company will keep launching its products into more than 130 markets globally and continue to make efforts to provide high-quality and highly accessible drugs to make people healthier. Furthermore, to keep its commitment to bring better life for people , Lotus has donated 10,000 boxes of chloroquine phosphate to Thailand, to help the country to overcome COVID-19 pandemic.
Lotus is a generic company headquartered in Taiwan with highvalue
generic products covering CNS, CVS, oncology, women
health, and anti-obesity drugs in tablets & hard/softgel capsule for
global markets.
